Login
Request Demo
Publications

Are high coronary risk patients missing out on lipid-lowering drugs in Australia?

To examine whether high coronary risk patients in Australia, where use of lipid-lowering drugs (LLD) is very high by international standards, are receiving LLD.

Authors: Leon A Simons and Eric Chung
Medical Journal Australia 2014; 201: 213-216

Download document

Download Now
high coronary risklipid-lowering drugs

Related Resources

Real-World Study: Treatment Persistence in Pulmonary Arterial Hypertension Patients

The study analysed real-world data to compare treatment persistence and adherence among PAH patients on ERAs in Japan. Results showed significantly higher persistence with a medication compared to the other two medications.

Real world use of antipsychotic medication

A recent publication using Prospection’s real-world data analytics shows, 1 in 5 Australian patients with schizophrenia [1] is medicated with older typical long acting injectable (LAI) antipsychotics. Schizophrenia is one of the top ten contributors to the global burden of...

A retrospective review of the persistence of bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.

Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage.

Patterns of Antipsychotic Medication Prescribing in Australia.

Schizophrenia is a mental health disorder characterised by hallucinations, delusions and disorganised behaviour. The Australian pharmaceutical benefits scheme (PBS) reimburse a number of antipsychotic therapies, however, there is little known around the patterns of utilisation and the patient characteristics of...